NXTC Reports $41.8M Cash, $55.8M Net Loss, SIM0505 Phase 1 Data Q2 2026, LNCB74 Dose Optimization H2 2026
NextCure, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $3.38
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS